Study of LusPACercept in Participants With Myelofibrosis Associated Anemia and Thrombocytopenia
A Phase 2 Multi-Institutional Study of Combination of Luspatercept With Pacritinib (LusPACercept) in Patients With Myelofibrosis Associated Anemia and Thrombocytopenia
This study is for participants who have been diagnosed with myelofibrosis with cytopenia. Luspatercept and Pacritinib are experimental drug combination that works by blocking certain enzymes to calm an overactive inmmune system to reduce inflammation which would allow red blood cells to mature. The purpose of this study is to find out if the combination of Luspatercept and Pacritinib can help improve hemobglobin or transfusion dependents in participants with myelofibrosis with cytopenias.
調査の概要
詳細な説明
Myelofibrosis is a type of bone cancer that mainly affects the elderly. Myeolofibrosis can either develop on its own, or it can be caused by other blood cell conditions. Myeolofibrosis causes scarring in the bone marrow that makes it hard to produce healthy read blood cells. This increases the risk of participants developing anemia at diagnosis, but eventually most affected participants develop anemia. Anemia is a complication of using Janus Kinase inhibitors, which are the main agents used to treat MF. Almost half of the participants who develop anemia require red blood cell transfusion support. Anemia causes poor quality of life, especially in participants who are transfusion dependent.
The goal of this study is to find out if using a combination of Luspatercept and Pacritinib can help decrease anemia in particpants with MF and improve the quality of life by requiring less blood transfusions. This combination works by blocking certain enzymes to calm an overactive immune system and reduce inflammation. This allows red blood cells to mature. Luspatercept will be given through subcutaneous injections on the first day of the study cycle, and pacritinib will be given in an oral pill that will be taken 2 times per day. About 50 participants are planned to be enrolled in the study.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Akriti Jain, MD, FACP
- 電話番号:216 445-7942
- メール:JAINA9@ccf.org
研究場所
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44196
- Cleveland Clinic Foundation
-
コンタクト:
- Akriti G Jain, MD, FACP
- 電話番号:216 445-7942
- メール:JAINA9@ccf.org
-
主任研究者:
- Akriti G Jain, MD, FACP
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patients with myelofibrosis as defined by WHO criteria - either primary or secondary myelofibrosis with:
-
Anemia:
- Transfusion Dependent: ≥3 units transfused in the 12 weeks immediately preceding C1D1.
- Non-Transfusion Dependent: had ≥3 Hb level measurements of ≤10 g/dL recorded on ≥3 different days with no RBC transfusions in the 12 weeks immediately preceding C1D1.
-
Thrombocytopenia: Platelet count of ≤150 at any time after signing informed consent.
-
-
Age ≥18 years
-
Participant has an Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2.
-
A female of childbearing potential (FCBP) for this study is defined as a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (eg, has had menses at any time in the preceding 24 consecutive months). Females of childbearing potential (FCBP) participating in the study must:
-
Have 2 negative pregnancy tests as verified by the Investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the study, and after end of IP. This applies even if the participant practices true abstinence* from heterosexual contact.
-
Either commit to true abstinence* from heterosexual contact (which must be reviewed on a monthly basis and source documented) or agree to use, and be able to comply with, effective contraception# 28 days prior to starting IP, during the study therapy (including dose interruptions), and for 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) after discontinuation of study therapy.
- Subjects must avoid concomitant use of pacritinib with hormonal contraceptives except for intrauterine systems containing levonorgestrel. The effectiveness of hormonal contraceptives, except for intrauterine systems containing levonorgestrel, may be reduced when used with pacritinib. If contraception is needed or desired, an alternate contraceptive that is not affected by CYP3A4 inducers (e.g., an intrauterine system) or additional nonhormonal contraceptive (e.g., condoms) should be used when treated concomitantly with pacritinib, and for 30 days after last dose of pacritinib
-
-
Male participants must:
Practice true abstinence* (which must be reviewed on a monthly basis) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential who is or is not using contraception** while participating in the study, during dose interruptions and for at least 12 weeks (approximately 5 times the mean terminal half-life of IP based on multiple-dose PK data) following IP discontinuation, even if he has undergone a successful vasectomy.
-
True abstinence is acceptable when it is in line with the preferred and usual lifestyle of the participant. [Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods) and withdrawal are not acceptable methods of contraception.]
-
Agreement to use highly effective methods of contraception that alone or in combination result in a failure rate of a Pearl index of less than 1% per year when used consistently and correctly throughout the course of the study. Such methods include: Placement of an intrauterine device (IUD); Bilateral tubal occlusion; Vasectomized partner; Sexual Abstinence.
- Participant is willing and able to adhere to the study visit schedule and other protocol requirements including the use of the electronic patient reported outcomes device.
- Participants must have the ability to understand and the willingness to sign a written informed consent document.
-
Exclusion Criteria:
- Prior use of Luspatercept, Sotatercept, Elritercept or any other activin ligand traps, pacritinib or Momelotinib for any duration. Prior Ruxolitinib or Fedratinib are permissible with a wash out period of 2 weeks prior to C1D1.
- Participant participation in any other clinical protocol or investigational trial that involves use of experimental therapy (including investigational agents) and/or therapeutic devices within 30 days or for investigational agents within five half-lives, whichever comes later, by the end of the screening period.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to luspatercept or pacritinib.
- Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, gastrointestinal (GI) disease, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
4.2.5. Participant with anemia from cause other than MF or JAK2 inhibitor therapy (eg, iron deficiency, vitamin B12 and/or folate deficiencies, autoimmune or hemolytic anemia, infection, or any type of known clinically significant bleeding or sequestration).
-
Participant use of hydroxyurea, immunomodulatory compounds such as pomalidomide, thalidomide, ESAs, androgenic steroids, strong CYP3A4 inhibitors and inducers, or other drugs with potential effects on hematopoiesis ≤ 2 weeks up to the end of the screening period.
- Systemic corticosteroids are permitted for nonhematological conditions providing the participant is receiving a constant dose equivalent to ≤ 10 mg prednisone for the 4 weeks immediately up to the end of the screening period. Use of topical steroids (drops, inhaler, ointment etc.) are permitted.
- Iron chelation therapy (ICT) is permitted providing the participant is receiving a stable dose for the 8 weeks up to the end of the screening period.
-
Participant with any of the following laboratory abnormalities at screening:
- Neutrophils: < 0.5 x 109/L
- White blood count (WBC): > 100 x 109/L
- Peripheral blood myeloblasts: > 10%
- PT or INR and PTT or aPTT >=1.5x ULN (this exclusion criteria would not apply for patients on anticoagulation).
- Estimated glomerular filtration rate: < 30 mL/min/1.73 m2 (via the 4-variable modification of diet in renal disease [MDRD] formula) or nephrotic participants (eg, urine albumin-to-creatinine ratio > 3500 mg/g)
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT): > 3.0 x upper limit of normal (ULN)
- Direct bilirubin: ≥ 2 x ULN
- Severe hepatic impairment defined as Child-Pugh Class C (score ≥10)
- Higher levels are acceptable if these can be attributed to active red blood cell precursor destruction within the bone marrow (eg, ineffective erythropoiesis) or due to pre-existing Gilbert's disease.
-
Participant with prior history of malignancies, other than disease under study, unless the participant has been free of the disease for ≥ 3 years. However, participants with the following history/concurrent conditions are allowed (if they have already undergone treatment with curative intent):
- Basal or squamous cell carcinoma of the skin
- Carcinoma in situ of the cervix
- Carcinoma in situ of the breast
- Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system)
-
Participant with a major bleeding event (defined as symptomatic bleeding in a critical area or organ and/or bleeding causing a decrease in Hgb of ≥ 2 g/dL or leading to transfusion of ≥ 2 units of packed red cells) in the last 3 months prior to the end of the screening period.
-
Participant with uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment).
-
Pregnant or breastfeeding females.
-
Subjects with QTc >480 (unless QRS prolongation >120 msec, in which case QTC up to 500 is acceptable)
-
Subjects who have experienced a thrombotic or embolic event during 6 months prior to first planned dose of luspatercept.
-
Subjects who have experienced a major cardiac event within 6 months prior to enrollment, including but not limited to hospitalization for congestive heart failure (CHF), myocardial infarction (MI), or clinically significant arrhythmia requiring medical intervention
-
Subjects who have experienced symptomatic heart failure defined as New York Heart Association (NYHA) Class II or greater at the time of enrollment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:LusPACercept combination
Luspatercept will be given through subcutaneous injection on Day 1of each cycle at a starting dose of 1.33 milligrams/kilogram and can go up to a maximum dose of 1.75 milligrams/kilogram. Pacritinib will be given twice daily orally at a dose of 200 milligrams. Each cycle lasts 21 days. |
Luspatercept will be given through subjecutaneous injection on Day 1of each cycle at a dose of 1.33-1.75mg/kg. Pacritinib will be given twice daily orally at a dose of 200mg. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rate of major response for anemia
時間枠:week 24
|
The rate of major response for anemia is defined as per 2024 IWG-ELN response criteria for transfusion dependent and non-transfusion dependent partipants with myelofibrosis. |
week 24
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rate of minor response for anemia
時間枠:week 24
|
Minor response for anemia is defined as per 2024 IWG-ELN response criteria for transfusion dependent and non-transfusion dependent partipants with myelofibrosis. |
week 24
|
|
Safety of luspatrecept and pacritinib combination
時間枠:up to 24 weeks
|
Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) according to the CTCAE. |
up to 24 weeks
|
|
Tolerability of luspatrecept and pacritinib combination
時間枠:up to 24 weeks
|
Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) according to the CTCAE. |
up to 24 weeks
|
|
Proportion of participants achieving an anemia response
時間枠:up to 24 weeks
|
Anemia response during the entire treatment period, defined as a greater than or equal to 1.5 g/dL increase in hemoglobin during the entire treatment period |
up to 24 weeks
|
|
Time to anemia response
時間枠:up to 24 weeks
|
Defined as time from first dose to first onset of anemia response during the 24 week primary treatment period |
up to 24 weeks
|
|
Duration of anemia response
時間枠:up to 24 weeks
|
Defined as the amount of time from the onset of longest anemia response to loss of that response per IWG ELN 2024 criteria during the primary treatment period |
up to 24 weeks
|
|
Proportion of participants achieving a greater than 50% reduction in total symptom score
時間枠:up to 24 weeks
|
As defined by the myeolofibrosis Symptom Assessment form v.4.0 (MF-SAF) |
up to 24 weeks
|
|
Change in spleen size
時間枠:up to 24 weeks
|
Evaluate change in spleen size, assessed by spleen length on ultrasound and palpable spleen length below the left costal margin |
up to 24 weeks
|
協力者と研究者
捜査官
- 主任研究者:Akriti Jain, MD, FACP、The Cleveland Clinic
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CASE2926
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
All participant data will be shared via peer-reviewed publication as a combined summary. Any individual outcomes published per subject will be deidentified utilizing the subject ID (eg. Dose level, demographics, adverse events etc.)
IPD 共有時間枠
Data included in the peer reviewed publication will be publicly available. No raw data will be shared.
IPD 共有アクセス基準
A peer-reviewed publication will be made available according to the publishing journal's specifications. CCF personnel will not share study data apart from that which has been published publicly
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。